NovoCure Ltd (NASDAQ: NVCR) kicked off on Tuesday, up 4.77% from the previous trading day, before settling in for the closing price of $15.73. Over the past 52 weeks, NVCR has traded in a range of $11.29-$24.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 17.16% over the past five years. While this was happening, its average annual earnings per share was recorded 32.97%. With a float of $97.35 million, this company’s outstanding shares have now reached $107.08 million.
Let’s look at the performance matrix of the company that is accounted for 1453 employees. In terms of profitability, gross margin is 76.41%, operating margin of -27.51%, and the pretax margin is -19.82%.
NovoCure Ltd (NVCR) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of NovoCure Ltd is 10.03%, while institutional ownership is 85.90%. The most recent insider transaction that took place on Nov 02 ’24, was worth 734. In this transaction Chief Operating Officer of this company sold 44 shares at a rate of $16.69, taking the stock ownership to the 3,459 shares. Before that another transaction happened on Oct 31 ’24, when Company’s Chief Human Resources Officer sold 810 for $15.79, making the entire transaction worth $12,792. This insider now owns 110,093 shares in total.
NovoCure Ltd (NVCR) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.45 earnings per share (EPS), higher than consensus estimate (set at -0.52) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 32.97% per share during the next fiscal year.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
Take a look at NovoCure Ltd’s (NVCR) current performance indicators. Last quarter, stock had a quick ratio of 1.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.39, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.58 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
NovoCure Ltd (NASDAQ: NVCR) saw its 5-day average volume 0.75 million, a negative change from its year-to-date volume of 1.29 million. As of the previous 9 days, the stock’s Stochastic %D was 14.98%. Additionally, its Average True Range was 1.08.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 23.81%, which indicates a significant decrease from 38.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.59% in the past 14 days, which was higher than the 68.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.53, while its 200-day Moving Average is $17.10. Nevertheless, the first resistance level for the watch stands at $16.90 in the near term. At $17.33, the stock is likely to face the second major resistance level. The third major resistance level sits at $18.10. If the price goes on to break the first support level at $15.70, it is likely to go to the next support level at $14.93. The third support level lies at $14.50 if the price breaches the second support level.
NovoCure Ltd (NASDAQ: NVCR) Key Stats
The company with the Market Capitalisation of 1.78 billion has total of 108,201K Shares Outstanding. Its annual sales at the moment are 509,340 K in contrast with the sum of -207,040 K annual income. Company’s last quarter sales were recorded 155,100 K and last quarter income was -30,570 K.
